We explore the current guidance for osteoporosis screening in men, as well as barriers to access for both clinicians and ...

The first patient was enrolled this month in a Nanostics-sponsored clinical utility study in Calgary to quantify the impact of incorporating ClarityDX Prostate into the standard of care for the ...

Artificial intelligence can help urologists and oncologists make treatment recommendations that are objective and evidence-based.

Nearly all men with a polygenic risk score in the 90th percentile or above had a 10-year absolute risk for prostate cancer exceeding 3.8%. A polygenic risk score (PRS) identifies more patients with ...